Hematopoiesis News

Hematopoiesis News is an online resource that provides updates on the latest research in the fields of hematopoiesis, blood, and bone marrow disorders.

Mutant NPM1 Hijacks Transcriptional Hub to Maintain Pathogenic Gene Programs in Acute Myeloid Leukemia

[Cancer Discovery] For the first time, scientists comprehensively proved nucleophosmin (NPM1c) bonded to a subset of active gene promoters in NPM1c AMLs, including well-known leukemia-driving genes – HOXA/B cluster genes and MEIS1.

Transient Regulation of RNA Methylation in Human Hematopoietic Stem Cells Promotes Their Homing and Engraftment

[Leukemia] Researchers demonstrated that inhibition of RNA decay by regulation of RNA methylation enhanced the expression of the homing receptor chemokine C-X-C receptor-4 in HSCs.

The ENL YEATS Epigenetic Reader Domain Critically Links MLL-ENL to Leukemic Stem Cell Frequency in t(11; 19) Leukemia

[Leukemia] Scientists found the YEATS domain was retained in 84.1% of MLL-ENL patients and crucial for MLL-ENL-mediated leukemogenesis in mouse models. Mechanistically, deletion of the YEATS domain impaired MLL-ENL fusion protein binding and decreased expression of pro-leukemic genes like Eya1 and Meis1.

Impdh Inhibition Activates Tlr-VCAM1 Pathway and Suppresses the Development of Mll-Fusion Leukemia

[EMBO Molecular Medicine] The authors found that AMLs with MLL-fusions were susceptible to Inosine monophosphate dehydrogenase inhibitors in vitro.

Modular UBE2H-Ctlh E2-E3 Complexes Regulate Erythroid Maturation

[eLife] By measuring the proteomic landscape of in vitro human erythropoiesis models, investigators found dynamic differential expression of subunits of the CTLH E3 ubiquitin ligase complex that formed maturation stage-dependent assemblies of topologically homologous RANBP9- and RANBP10-CTLH complexes.

HDAC1/3-Dependent Moderate Liquid–Liquid Phase Separation of YY1 Promotes METTL3 Expression and Aml Cell Proliferation

[Cell Death & Disease] In the current study, researchers uncovered that Yin Yang 1 (YY1) bonded to the promoter region of METTL3 as a transcription factor and promoted its expression, which in turn enhanced the proliferation of AML cells

Total Body Irradiation plus Fludarabine versus Busulfan plus Fludarabine as a Myeloablative Conditioning for Adults with Acute Myeloid Leukemia Treated with Allogeneic Hematopoietic Cell...

[Bone Marrow Transplantation] Investigators compared retrospectively, total body irradiation plus Flu versus busulfan plus Flu as myeloablative conditioning before allogeneic hematopoietic cell transplantation (allo-HCT) in patients with AML.

Predicting the Loss of Hepatitis B Surface Antigen Following Hematopoietic Stem Cell Transplantation in Patients with Chronic HBV Infection

[Bone Marrow Transplantation] A total of 62 patients with chronic hepatitis B virus infection achieved hepatitis B surface antigen (HBsAg) loss after allogeneic hematopoietic stem cell transplantation (allo-HSCT).

Paired Bone Marrow and Peripheral Blood Samples Demonstrate Lack of Widespread Dissemination of Some CH Clones

[Blood Advances] Researchers showed that patients with osteoarthritis had a high prevalence of clonal hematopoiesis (CH), involving genes encoding epigenetic modifiers and DNA damage repair pathway proteins.

CHIP Happens: Clonal Hematopoiesis of Indeterminate Potential and Its Relationship to Solid Tumors

[Clinical Cancer Research] The authors review the role of CHIP mutations in clonal expansion of hematopoietic cells, explore the relationship between CHIP and solid tumors, and discuss the potential roles of CHIP in inflammation and solid tumor biology.

The Present and Future of Measurable Residual Disease Testing in Acute Myeloid Leukemia

[Haematologica] Researchers review the current approaches to measurable residual disease (MRD) testing in AML, discuss strengths and limitations, highlight recent technological advances that may improve such testing, and summarize ongoing initiatives to generate the clinical evidence needed to advance the use of MRD testing in patients with AML.

Imago BioSciences Announces First Participant Dosed in Investigator-Sponsored Phase I Study of Bomedemstat in Combination with Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia

[Imago BioSciences, Inc.] Imago BioSciences, Inc. announced that the first participant had been dosed in an investigator-sponsored Phase I study of bomedemstat, an investigational oral lysine-specific demethylase 1 inhibitor, in combination with venetoclax (Venclexa®) in patients with relapsed or refractory AML.

Hematopoiesis News curates the top publications and reviews covering the regulation, expression patterns, differentiation and characterization of hematopoietic stem cells, as well as blood and bone marrow disorders. We also feature the latest job postings and upcoming conferences in the hematopoiesis field.

spot_img